PT - JOURNAL ARTICLE AU - Helle Zacho AU - Mads R Jochumsen AU - Niels C Langkilde AU - Jesper C Mortensen AU - Christian Haarmark AU - Helle W Hendel AU - Jørgen B Jensen AU - Lars J. Petersen TI - No added value of <sup>18</sup>F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy AID - 10.2967/jnumed.119.229062 DP - 2019 May 01 TA - Journal of Nuclear Medicine PG - jnumed.119.229062 4099 - http://jnm.snmjournals.org/content/early/2019/05/30/jnumed.119.229062.short 4100 - http://jnm.snmjournals.org/content/early/2019/05/30/jnumed.119.229062.full AB - Aim: To determine if additional 18F-sodium fluoride PET/CT (NaF-PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF-PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels&lt;0.2 ng/mL at six weeks and six months postoperatively, PSA level≥0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; seventy-five patients (93%) achieved biochemical responses, six patients had biochemical failure. NaF-PET/CT indicated bone metastasis in one patient (1.2%), was equivocal in seven patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF-PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF-PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF-PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.